<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2023-38-4-40-45</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-2049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Определение роли лабораторных маркеров в прогнозировании эффективности катетерного лечения фибрилляции предсердий: обзор литературы</article-title><trans-title-group xml:lang="en"><trans-title>The role of laboratory markers in predicting the effectiveness of catheter treatment for atrial fibrillation: a literature review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3483-3380</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдуллаева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdullaeva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдуллаева Айшат Алигаджиевна, аспирант, отдел нарушений сердечного ритма и проводимости сердца, </p><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Aishat A. Abdullaeva, Graduate Student, Cardiac Arrhythmia Department</p><p>10, Build. 3, Petroverigsky per., Moscow, 101990</p></bio><email xlink:type="simple">ishat.abdullaeva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6297-5741</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арипова</surname><given-names>Н. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Aripova</surname><given-names>N. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арипова Назира Рустамовна, аспирант, отдел нарушений сердечного ритма и проводимости сердца</p><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Nazira R. Aripova, Graduate Student, Cardiac Arrhythmia Department</p><p>10, Build. 3, Petroverigsky per., Moscow, 101990</p></bio><email xlink:type="simple">anazira9696@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1544-4902</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Злобина</surname><given-names>П. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Zlobina</surname><given-names>P. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Злобина Полина Дмитриевна, аспирант, отдел нарушений сердечного ритма и проводимости сердца</p><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Polina D. Zlobina, Graduate Student, Cardiac Arrhythmia Department</p><p>10, Build. 3, Petroverigsky per., Moscow, 101990</p></bio><email xlink:type="simple">paska0@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6855-4857</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харлап</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kharlap</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Харлап Мария Сергеевна, канд. мед. наук, ведущий научный сотрудник, отдел нарушений сердечного ритма и проводимости сердца</p><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Maria S. Kharlap, Cand. Sci. (Med.), Leading Research Scientist, Cardiac Arrhythmia Department</p><p>10, Build. 3, Petroverigsky per., Moscow, 101990</p></bio><email xlink:type="simple">kharlapmaria@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3788-3997</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давтян</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Davtyan</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Давтян Карапет Воваевич, д-р мед. наук, профессор, руководитель отдела нарушений сердечного ритма и проводимости</p><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>Karapet V. Davtyan, Dr. Sci. (Med.), Professor, Head of Cardiac Arrhythmia Department</p><p>10, Build. 3, Petroverigsky per., Moscow, 101990</p></bio><email xlink:type="simple">kdavtyan@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр терапии и профилактической медицины Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2023</year></pub-date><volume>38</volume><issue>4</issue><fpage>40</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Абдуллаева А.А., Арипова Н.Р., Злобина П.Д., Харлап М.С., Давтян К.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Абдуллаева А.А., Арипова Н.Р., Злобина П.Д., Харлап М.С., Давтян К.В.</copyright-holder><copyright-holder xml:lang="en">Abdullaeva A.A., Aripova N.R., Zlobina P.D., Kharlap M.S., Davtyan K.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/2049">https://www.sibjcem.ru/jour/article/view/2049</self-uri><abstract><p>Фибрилляция предсердий (ФП) – наиболее часто встречающееся нарушение ритма сердца среди взрослого населения. Известно множество вероятных причин возникновения ФП: структурные заболевания сердца, воспалительные и аутоиммунные заболевания, ожирение, злоупотребление алкоголем, сахарный диабет, обструктивное апноэ сна, пожилой возраст. Эктопическая активность муфт из легочных вен лежит в патогенезе пароксизмальной и персистирующей форм ФП. Доказана роль и самой ФП в запуске воспалительного процесса в миокарде предсердия. Несмотря на большое количество существующих данных, продолжаются вестись поиски причин развития ФП. Ранее ФП считалась исходом длительного гемодинамического стресса, артериальной гипертензии и клапанной болезни сердца. В последнее время взгляды на патогенез ФП изменились, поскольку все чаще встречаются пациенты с метаболическими заболеваниями, без гипертрофии левого желудочка (ГЛЖ) и дилатации ЛЖ, но с нарушениями структуры и функции предсердий, наиболее часто левого предсердия (ЛП). Активно проводятся поиски лабораторных маркеров для определения групп пациентов, наиболее подверженных развитию ФП. Определение причины развития ФП и патогенеза у каждого больного является важным для подбора терапии и определения тактики лечения. В настоящее время ведется поиск лабораторных маркеров, которые могут быть ассоциированы с манифестацией ФП, атриопатией, эффективностью / неэффективностью катетерного лечения ФП. Был проведен анализ клинических исследований на основе статей, индексируемых в базах данных Scopus, ВАК, Российском индексе научного цитирования, PubMed, Web of Science.</p></abstract><trans-abstract xml:lang="en"><p>Atrial fibrillation (AF) is the most common cardiac arrhythmia among the adult population. There are many possible causes of AF: structural heart disease, inflammatory and autoimmune diseases, obesity, alcohol abuse, diabetes mellitus, obstructive sleep apnea and old age. The ectopic activity of pulmonary vein couplings lies in the pathogenesis of paroxysmal and persistent forms of AF. The role of AF itself in triggering the inflammatory process in the atrium myocardium has also been proven. Despite the large amount of existing data, the search for the causes of AF continues. Previously, AF was considered the outcome of prolonged hemodynamic stress, arterial hypertension and valvular heart disease. Recently, views on the pathogenesis of AF have changed, since patients with metabolic diseases, without hypertrophy and dilatation of the left ventricle, but with disturbances in the structure and function of the atria, most often the left atrium, are increasingly encountered. There is an active search for laboratory markers to identify groups of patients most susceptible to developing AF. Determining the cause of atrial fibrillation and pathogenesis in each patient is important for selecting therapy and determining treatment tactics. Currently, a search is underway for laboratory markers that may be associated with the manifestation of atrial fibrillation, with atriopathy, and the effectiveness/ineffectiveness of catheter treatment for atrial fibrillation. An analysis of clinical studies was carried out based on articles indexed in the Scopus, VAK, Russian Science Citation Index, PubMed, and Web of Science databases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>катетерное лечение фибрилляции предсердий</kwd><kwd>лабораторные маркеры эффективности катетерного лечения</kwd><kwd>криобаллонная изоляция устьев легочных вен</kwd><kwd>прогнозирование эффективности катетерного лечения фибрилляции предсердий</kwd><kwd>патогенез фибрилляции предсердий</kwd><kwd>атриопатия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>catheter treatment for atrial fibrillation</kwd><kwd>laboratory markers of the effectiveness of catheter treatment</kwd><kwd>cryoballoon isolation of the pulmonary vein ostia</kwd><kwd>prediction of the effectiveness of catheter treatment of atrial fibrillation</kwd><kwd>pathogenesis of atrial fibrillation</kwd><kwd>atriopathy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaway C.W., Carson A.P et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A report from the American Heart Association. Circulation. 2019;139(10):e56–e528. DOI: 10.1161/CIR.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaway C.W., Carson A.P et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A report from the American Heart Association. Circulation. 2019;139(10):e56–e528. DOI: 10.1161/CIR.0000000000000659.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Haïssaguerre M., Jaïs P., Shah D.C., Takahashi A., Hocini M., Quiniou G. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998;339(10):659–666. DOI: 10.1056/NEJM199809033391003.</mixed-citation><mixed-citation xml:lang="en">Haïssaguerre M., Jaïs P., Shah D.C., Takahashi A., Hocini M., Quiniou G. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998;339(10):659–666. DOI: 10.1056/NEJM199809033391003.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Давтян К.В., Калемберг А.А., Царева Е.Н., Благова О.В., Харлап М.С. Роль воспалительной теории в патогенезе фибрилляции предсердий. Российский кардиологический журнал. 2019;(7):110–114. DOI: 10.15829/1560-4071-2019-7-110-114.</mixed-citation><mixed-citation xml:lang="en">Davtyan K.V., Kalemberg A.A., Tsareva E.N., Blagova O.V., Harlap M.S. The role of inflammatory theory in the pathogenesis of atrial fibrillation. Russian Journal of Cardiology. 2019;(7):110–114. (In Russ.). DOI: 10.15829/1560-4071-2019-7-110-114.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Яшин С. М., Шубик Ю.В. Атриопатия и фибрилляция предсердий. Часть I. Вестник Санкт-Петербургского университета. Медицина. 2022;(17)4:254–271. DOI: 10.21638/spbu11.2022.402.</mixed-citation><mixed-citation xml:lang="en">Jashin S. M., Shubik Ju.V. Atriopathy and atrial fibrillation. Part I. Vestnik of Saint Petersburg University. Medicine. 2022;(17)4:254–271. DOI: 10.21638/spbu11.2022.402.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Goette A., Kalman J.M., Aguinaga L., Akar J., Cabrera J.A., Chen S.A. et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm. 2017;14(1):e3–e40. DOI: 10.1016/j.hrthm.2016.05.028.</mixed-citation><mixed-citation xml:lang="en">Goette A., Kalman J.M., Aguinaga L., Akar J., Cabrera J.A., Chen S.A. et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm. 2017;14(1):e3–e40. DOI: 10.1016/j.hrthm.2016.05.028.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hoit B.D. Left atrial size and function: role in prognosis. J. Am. Coll. Cardiol. 2014;63(6):493–505. DOI: 10.1016/j.jacc.2013.10.055.</mixed-citation><mixed-citation xml:lang="en">Hoit B.D. Left atrial size and function: role in prognosis. J. Am. Coll. Cardiol. 2014;63(6):493–505. DOI: 10.1016/j.jacc.2013.10.055.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Li H., Liu C., Ren Y., Sun C. NT Pro-BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement. Clin. Cardiol. 2022;45(1):68–74. DOI: 10.1002/clc.23760.</mixed-citation><mixed-citation xml:lang="en">Zhao X., Li H., Liu C., Ren Y., Sun C. NT Pro-BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement. Clin. Cardiol. 2022;45(1):68–74. DOI: 10.1002/clc.23760.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart. J. 2013;34(20):1475– 1480. DOI: 10.1093/eurheartj/eht024.</mixed-citation><mixed-citation xml:lang="en">Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart. J. 2013;34(20):1475–1480. DOI: 10.1093/eurheartj/eht024.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical Cohorts for Validation of New Digital Biomarkers (MAESTRIA). Electronic resource. URL: https://clinicaltrials.gov/study/NCT05855538?cond=Atrial%20Fibrillation&amp;term=Biomarkers&amp;rank=9 (14.11.2023).</mixed-citation><mixed-citation xml:lang="en">Clinical Cohorts for Validation of New Digital Biomarkers (MAESTRIA). Electronic resource. URL: https://clinicaltrials.gov/study/NCT05855538?cond=Atrial%20Fibrillation&amp;term=Biomarkers&amp;rank=9 (14.11.2023).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Царева Е.Н., Давтян К.В., Топчян А.Г., Харлап М.С., Калемберг А.А., Брутян А.А. и др. Изучение взаимосвязи маркеров воспаления в сыворотке крови и рецидивирования фибрилляции предсердий у пациентов, перенесших катетерную изоляцию легочных вен. Кардиоваскулярная терапия и профилактика. 2020;19(5):2579. DOI: 10.15829/1728-8800-2020-2579.</mixed-citation><mixed-citation xml:lang="en">Tsareva E.N., Davtyan K.V., Topchyan A.G., Kharlap M.S., Kalemberg A.A., Brutyan A.A. et al. Relationship between serum inflammatory markers and recurrent atrial fibrillation in patients undergoing pulmonary vein isolation. Cardiovascular Therapy and Prevention. 2020;19(5):2579. (In Russ.). DOI: 10.15829/1728-8800-2020-2579.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wozakowska-Kapłon B., Bartkowiak R., Grabowska U., Janiszewska G. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation – clinical significance. Kardiol. Pol. 2010;68(7):781–786. https://pubmed.ncbi.nlm.nih.gov/20648436/ (14.11.2023).</mixed-citation><mixed-citation xml:lang="en">Wozakowska-Kapłon B., Bartkowiak R., Grabowska U., Janiszewska G. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation – clinical significance. Kardiol. Pol. 2010;68(7):781–786. https://pubmed.ncbi.nlm.nih.gov/20648436/ (14.11.2023).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ellinor P.T., Low A.F., Patton K.K., Shea M.A., Macrae C.A. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J. Am. Coll. Cardiol. 2005;45(1):82–86. DOI: 10.1016/j.jacc.2004.09.045.</mixed-citation><mixed-citation xml:lang="en">Ellinor P.T., Low A.F., Patton K.K., Shea M.A., Macrae C.A. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J. Am. Coll. Cardiol. 2005;45(1):82–86. DOI: 10.1016/j.jacc.2004.09.045.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Higa C., Ciambrone G., Donato M.S., Gambarte G., Rizzo N., Escobar A. et al. Descenso de los niveles de propéptido natriurético de tipo B-N terminal luego de la reversión de pacientes con fibrilación auricular y función ventricular conservada [NT-Pro-BNP levels performance before and after reversion to sinus rhythm in patients with preserved ventricular function]. Medicina (B Aires). 2011;71(2):146–150. (In Spanish). http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0025-76802011000200006&amp;lng=es (14.11.2023).</mixed-citation><mixed-citation xml:lang="en">Higa C., Ciambrone G., Donato M.S., Gambarte G., Rizzo N., Escobar A. et al. Descenso de los niveles de propéptido natriurético de tipo B-N terminal luego de la reversión de pacientes con fibrilación auricular y función ventricular conservada [NT-Pro-BNP levels performance before and after reversion to sinus rhythm in patients with preserved ventricular function]. Medicina (B Aires). 2011;71(2):146–150. (In Spanish). http://www.scielo.org.ar/scielo.php?script=sci_arttext&amp;pid=S0025-76802011000200006&amp;lng=es (14.11.2023).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jayachandran T., Johnson F. N-terminal pro-brain natriuretic peptide and atrial fibrillation. Indian. Pacing Electrophysiol. J. 2009;9(1):1–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615056/ (14.11.2023).</mixed-citation><mixed-citation xml:lang="en">Jayachandran T., Johnson F. N-terminal pro-brain natriuretic peptide and atrial fibrillation. Indian. Pacing Electrophysiol. J. 2009;9(1):1–4. https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2615056/ (14.11.2023).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rørth R., Jhund P.S., Yilmaz M.B., Kristensen S.L., Welsh P., Desai A.S. et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circ. Heart Fail. 2020;13(2):e006541. DOI: 10.1161/CIRCHEARTFAILURE.119.006541.</mixed-citation><mixed-citation xml:lang="en">Rørth R., Jhund P.S., Yilmaz M.B., Kristensen S.L., Welsh P., Desai A.S. et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circ. Heart Fail. 2020;13(2):e006541. DOI: 10.1161/CIRCHEARTFAILURE.119.006541.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cunha P.S., Laranjo S., Heijman J., Oliveira M.M. The atrium in atrial fibrillation – A clinical review on how to manage atrial fibrotic substrates. Front. Cardiovasc. Med. 2022;(9):879984. DOI: 10.3389/fcvm.2022.879984.</mixed-citation><mixed-citation xml:lang="en">Cunha P.S., Laranjo S., Heijman J., Oliveira M.M. The atrium in atrial fibrillation – A clinical review on how to manage atrial fibrotic substrates. Front. Cardiovasc. Med. 2022;(9):879984. DOI: 10.3389/fcvm.2022.879984.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Камардинов Д.Х., Сонгуров Р.Н., Иошина В.И., Бузиашвили Ю.И. Растворимый ST2 – как биомаркер, инструмент стратификации риска и терапевтическая мишень у пациентов с хронической сердечной недостаточностью. Кардиология. 2020;60(2):111–121. DOI: 10.18087/cardio.2020.3.</mixed-citation><mixed-citation xml:lang="en">Kamardinov D.K., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. Soluble ST2 – as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure. Kardiologiia. 2020;60(2):111–121. (in Russ.). DOI: 10.18087/cardio.2020.3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M. Characterization, pathogenesis, and clinical implications of inflammation-related atrial myopathy as an important cause of atrial fibrillation. J. Am. Heart Assoc. 2020;9(7):e015343. DOI: 10.1161/JAHA.119.015343.</mixed-citation><mixed-citation xml:lang="en">Packer M. Characterization, pathogenesis, and clinical implications of inflammation-related atrial myopathy as an important cause of atrial fibrillation. J. Am. Heart Assoc. 2020;9(7):e015343. DOI: 10.1161/JAHA.119.015343.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zou C., Zhang Z., Zhao W., Li G., Ma G., Yang X. et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J. Transl. Med. 2013;11:7. DOI: 10.1186/1479-5876-11-7.</mixed-citation><mixed-citation xml:lang="en">Zou C., Zhang Z., Zhao W., Li G., Ma G., Yang X. et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J. Transl. Med. 2013;11:7. DOI: 10.1186/1479-5876-11-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gurses K.M., Yalcin M.U., Kocyigit D., Kesikli S.A., Canpolat U., Yorgun H. et al. M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation. Europace. 2015;17(2):239–246. DOI: 10.1093/europace/euu228.</mixed-citation><mixed-citation xml:lang="en">Gurses K.M., Yalcin M.U., Kocyigit D., Kesikli S.A., Canpolat U., Yorgun H. et al. M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation. Europace. 2015;17(2):239–246. DOI: 10.1093/europace/euu228.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Гизатулина Т.П., Мартьянова Л.У., Белоногов Д.В., Мамарина А.В., Колунин Г.В., Петелина Т.И. и др. Прогнозирование площади низ ковольтажных зон в левом предсердии у пациентов с неклапанной фибрилляцией предсердий с помощью неинвазивных маркеров. Вестник аритмологии. 2023;30(3):32–39. DOI: 10.35336/VA-1161.</mixed-citation><mixed-citation xml:lang="en">Gizatulina T.P., Martyanova L.U., Belonogov D.V., Mamarina A.V., Kolunin G.V., Petelina T.I., Gorbatenko E.A. Prediction of low-voltage areas in the left atrium in patients with non-valvular atrial fibrillation by non-invasive markers. Journal of Arrhythmology. 2023;30(3):32–39. (In Russ.). DOI: 10.35336/VA-1161.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Арчаков Е.А., Баталов Р.Е., Эшматов О.Р., Степанов И.В., Муслимова Э.Ф., Реброва Т.Ю. и др. Эффективность катетерного лечения фибрилляции предсердий у пациентов с миокардитом в зависимости от адренореактивности организма (проспективное одноцентровое исследование). Вестник Российской академии медицинских наук. 2023;78(2):151–159. DOI: 10.15690/vramn8334.</mixed-citation><mixed-citation xml:lang="en">Archakov E.A., Batalov R.E., Eshmatov O.R., Stepanov I.V., Muslimova E.F., Rebrova T.Y. et al. Efficacy of catheter treatment of atrial fibrillation in patients with myocarditis depending on the adrenoreaction of the body (a prospective single-center study). Annals of the Russian Academy of Medical Sciences. 2023;78(2):151–159. (In Russ.). DOI: 10.15690/vramn8334.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
